Get the Stockscreener App
1.205
2.52%
0.015
Tscan Therapeutics Inc stock is traded at $1.205, with a volume of 35,130.
It is up +2.52% in the last 24 hours and down -44.55% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.19
Open:
$1.18
24h Volume:
35,130
Relative Volume:
0.06
Market Cap:
$63.23M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-0.6732
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
+5.17%
1M Performance:
-44.55%
6M Performance:
-8.27%
1Y Performance:
-76.76%
1-Day Range:
$1.1736
$1.2103
1-Week Range:
$1.02
$1.25
52-Week Range:
$1.02
$5.30
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.205 | 67.53M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.16 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.86 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.40 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.76 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
379.50 | 41.77B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
TScan Therapeutics Reports Increased Revenue Amid Rising Losses - TipRanks
Published on: 2025-11-12 17:29:17 - newser.com
Tscan Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Best data tools to analyze TScan Therapeutics Inc. stockCPI Data & Capital Protection Trade Alerts - newser.com
TScan Therapeutics Draws Analyst Optimism Despite Growing Losses - Finimize
TScan Therapeutics, Inc. Q3 Loss Increases, But Beats Estimates - Nasdaq
TScan Therapeutics Q3 revenue jumps - MarketScreener
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
TScan (NASDAQ: TCRX) secures FDA agreement on TSC-101 pivotal design; runway to 2027 - Stock Titan
What technical models suggest about TScan Therapeutics Inc.’s comeback2025 Valuation Update & Precise Buy Zone Identification - newser.com
Tscan Therapeutics Inc (TCRX) is looking forward to a strong quarter - setenews.com
Applying sector rotation models to TScan Therapeutics Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Trend analysis for TScan Therapeutics Inc. this weekProduct Launch & Safe Entry Zone Tips - newser.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Using data filters to optimize entry into TScan Therapeutics Inc. - newser.com
Should you wait for a breakout in TScan Therapeutics Inc.2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Is TScan Therapeutics Inc. building a consolidation baseShare Buyback & Fast Gain Stock Tips - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesWeekly Stock Recap & Daily Oversold Bounce Ideas - newser.com
Technical signs of recovery in TScan Therapeutics Inc.Weekly Loss Report & Free Low Drawdown Momentum Trade Ideas - newser.com
What analysts say about TScan Therapeutics Inc stockEnergy Sector Updates & Access Free Tools and Start Investing - earlytimes.in
Applying chart zones and confluence areas to TScan Therapeutics Inc.2025 Top Gainers & Consistent Profit Alerts - newser.com
Reversal indicators forming on TScan Therapeutics Inc. stockTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fearsAnalyst Downgrade & Safe Capital Growth Plans - newser.com
FY2025 EPS Forecast for TScan Therapeutics Raised by Analyst - Defense World
How TScan Therapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Market Mood & Low Risk Profit Maximizing Plans - Fundação Cultural do Pará
Is TScan Therapeutics Inc. stock attractive for ETFsCPI Data & AI Driven Price Forecasts - Fundação Cultural do Pará
Can TScan Therapeutics Inc. stock maintain growth trajectoryPrice Action & Advanced Swing Trade Entry Plans - newser.com
Growth Value: Will TScan Therapeutics Inc. stock benefit from green energy trendsEarnings Recap Summary & Detailed Earnings Play Strategies - Fundação Cultural do Pará
Can swing trading help recover from TScan Therapeutics Inc. lossesEarnings Miss & Fast Gain Stock Trading Tips - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economy2025 Top Gainers & Technical Pattern Alert System - newser.com
TScan Therapeutics (NASDAQ:TCRX) Price Target Cut to $6.00 by Analysts at Needham & Company LLC - Defense World
TScan Therapeutics (TCRX) Projected to Post Earnings on Tuesday - MarketBeat
Is TScan Therapeutics Inc. stock gaining market share2025 Buyback Activity & Smart Investment Allocation Insights - Fundação Cultural do Pará
TScan Therapeutics (NASDAQ:TCRX) Price Target Lowered to $6.00 at Needham & Company LLC - MarketBeat
The time has not yet come to remove your chips from the table: Tscan Therapeutics Inc (TCRX) - setenews.com
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
Barclays Reaffirms Their Buy Rating on TScan Therapeutics (TCRX) - The Globe and Mail
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
0.16%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):